mrr pvt. Ltd.

Metastatic Pancreatic Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017

Press Release   •   Jan 23, 2017 15:07 IST

p { margin-bottom: 0.25cm; line-height: 120%; }a:link { }

DelveInsights Report, Metastatic Pancreatic Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Metastatic Pancreatic Cancer Report is to understand the market and pipeline status of the drugs around the Metastatic Pancreatic Cancer to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline startegies. The DelveInsights Report provides the historical and forecasted sales of the drugs till 2018. The Report gives insights into patents providing the patent protection data and marketing exclusivity of all the drugs across the Metastatic Pancreatic Cancer. While the leading brands, companies and chemicals are considered thoroughly, DelveInsights report also provides details on the Global API Manufacturers across the globe covering Drug Master Filings of US, Europe and API Manufacturers in Asia specifically China and India.

Please note:This report requires certain updates. We have all the information available but require 48-72 Hours to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


A snapshot of the global Market and Phase III therapeutics scenario for Metastatic Pancreatic Cancer.

A review of the marketed products under prescription for Metastatic Pancreatic Cancer, regulatory information and marketing status.

Coverage of global patent coverage and detailed commentaries on the US patent challenges.

Graphical representation of investigational products for patent expiry and market exclusivities across the globe.

Product profiles for marketed products for Metastatic Pancreatic Cancer with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical details.

Coverage of API Manufacturers for Metastatic Pancreatic Cancer drugs in the United States, Europe and Asian Regions with location details.

Coverage of Regulatory filings in theUS, Europe, and Asia specifically India and China for Metastatic Pancreatic Cancer drugs.

Coverage of Route of Synthesis of Active Pharmaceutical Ingredient associated with Metastatic Pancreatic Cancer drugs.

Coverage of Metastatic Pancreatic Cancer Phase III pipeline products featuring sections on product description, mechanism of action, Chemical details and research & development progress.

Coverage of the United States Drug Master File (US DMF) available for Phase III Pipeline Drugs.

Key discontinued Marketed products.

Global Sales Figure to 2018.

Download Sample Copy of This Report at: